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Kaposi’s sarcoma-associated herpesvirus (KSHV) is associated with several different human malignancies,
including Kaposi’s sarcoma, primary effusion lymphoma, and multicentric Castleman’s disease. KSHV establishes
lifelong latency in the host and modulates the host immune response. Innate immunity is critical for controlling de
novo viral infection. Toll-like receptors (TLRs) are key components of the innate immune system, and they serve as
pathogen recognition receptors that stimulate the host antiviral response. In particular, TLR3 has been implicated
in RNA virus recognition. Currently, there is no information regarding how KSHV infection modulates any TLR
pathway. We report the first evidence that KSHV upregulates TLR3 expression in human monocytes during
primary infection. This is also the first demonstration of a human DNA tumor virus upregulating TLR3, a TLR that
thus far has been associated with the recognition of RNA viruses. We found that KSHV upregulates the TLR3
pathway and induces TLR3-specific cytokines and chemokines, including beta 1 interferon (IFN-1) and CXCL10
(IP-10). Small interfering RNAs directed against TLR3 greatly reduced the ability of KSHV to upregulate IFN-1
and CXCL10 upon infection.
Kaposi’s sarcoma-associated herpesvirus (KSHV) is the eti-
ological agent of Kaposi’s sarcoma, the most common neo-
plasm of human immunodeficiency virus (HIV)-infected pa-
tients (21, 53). KSHV is also the causative agent of two
lymphoproliferative diseases, primary effusion lymphoma and
multicentric Castleman’s disease (1, 21, 39, 53). KSHV, also
named human herpesvirus 8, is a gamma-2 herpesvirus that can
establish lifelong latency in its host. In order to enter the latent
phase following primary infection, the virus must modulate the
host innate immune response to allow for the establishment of
latency (23, 40, 44).
Toll-like receptors (TLRs) are one of the key components of
the innate immune system. TLRs are classified as pattern rec-
ognition receptors, as they recognize invading pathogens (2, 3,
55). Currently, there are 10 identified human TLRs. The TLR
family of proteins are transmembrane proteins with an immu-
noglobulinlike extracellular domain and an intracellular do-
main which contains Toll/interleukin-1 (IL-1) receptor (TIR)
domains through which the TLRs initiate their cell signaling
cascade (55). All TLRs contain anywhere from 21 to 25
leucine-rich repeats in their extracellular domains which rec-
ognize and bind to pathogen-associated molecular patterns on
the surface of the incoming pathogen (10). However, not all
TLRs are expressed at the cell surface. TLR3, -7, -8, and -9 are
all expressed in intracellular compartments (4, 5). Current
research has identified TLR2, -3, -4, -7, -8, and -9 as being
involved in the recognition of viruses through binding to RNA,
DNA, or viral glycoproteins (4, 5, 34). Thus far, TLR3 and
TLR7 have been reported to be induced by RNA. TLR3 can
recognize single-stranded RNA (ssRNA) and double-stranded
RNA (dsRNA), while TLR7 can recognize ssRNA (2, 5, 7, 18,
32, 33, 49, 50, 54). Both of these ligands (ssRNA and dsRNA)
are common intermediates in RNA virus replication. TLRs can
also recognize DNA viruses and DNA motifs; for example,
TLR9 recognizes CpG DNA motifs (8, 30). There is recent
evidence implicating a role for TLRs in herpesvirus infection.
TLR2 and TLR4 have been shown to recognize several her-
pesviruses, including herpes simplex virus 1 (HSV-1) and hu-
man cytomegalovirus (12, 22, 29, 66). Epstein-Barr virus has
recently been shown to upregulate TLR7 (38). Additionally,
Zhang et al. have recently reported that TLR3 deficiency in
humans leads to the uncontrolled spread of HSV-1 and to
HSV-1 encephalitis (68).
There are two basic pathways that TLRs use for signaling,
one being dependent on the adaptor protein MyD88 and the
other being a MyD88-independent pathway (3, 4). All TLRs,
with the exception of TLR3, signal through the MyD88-depen-
dent pathway. TLR3 is unique in that the initial signaling
cascade begins with the binding of TRIF (the TIR domain-
containing adaptor inducing beta interferon [IFN-]) to the
TIR binding domains within the intracellular domains of TLR3
(31, 67). TRIF, as indicated by its name, has been shown to be
responsible for the activation of IFN- and also for nuclear
factor kappa B (NF-B), both of which are important immu-
noregulatory proteins (4, 7). TLR3 can activate cytokines
downstream via two separate pathways, one involving inter-
feron regulatory transcription factor 3 (IRF3) and IRF7 and
the other involving TRAF6 and the interleukin receptor-asso-
ciated kinase family of kinases (3, 4, 49). The result of both of
these pathways is the upregulation of signature cytokines and
chemokines, primarily CXCL10, CCL-2, and IL-6, among oth-
ers (18, 42). Activation of the interferon response is also a
consequence of TLR3 activation, as it is for the activation of
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most TLRs (4). The role of TLRs in response to KSHV infec-
tion has not yet been elucidated.
Previous studies have shown that KSHV can successfully
infect human monocytes and macrophages both in vitro and in
vivo (11, 20). Blasig et al. detected viral replication in KSHV
lesions and identified the cells of origin as monocytes within
the lesion (11). Caselli et al. showed that coinfection of mono-
cytes with KSHV and HIV greatly increased the replication of
HIV in the presence of KSHV (20). Rappocciolo et al. re-
ported that KSHV uses DC-SIGN to enter monocyte-derived
macrophages and dendritic cells (43). Because monocytes are
infected in vivo by KSHV, we chose to analyze the TLR re-
sponse to KSHV infection in THP-1 monocytes as well as in
primary human monocytes.
In this study, we present evidence that KSHV infection re-
sults in the upregulation of TLR3 expression in THP-1 mono-
cytes and primary human monocytes. This is the first evidence
that a human DNA tumor virus specifically upregulates TLR3,
which until now has only been shown to signal in response to
RNA viruses. We also show that as a direct result of this TLR3
activation, there is strong upregulation of signature cytokines
and chemokines in KSHV-infected cells, in particular CXCL10, a
potent chemoattractant of monocytes, T cells, and neutrophils.
MATERIALS AND METHODS
Cell culture. THP-1 monocytes were maintained in RPMI 1640 medium
(Cellgro) containing 10% fetal bovine serum (FBS), 1% penicillin-streptomycin
(P-S), and 0.05 M 2-mercaptoethanol. Vero cells stably expressing KSHV-green
fluorescent protein were the kind gift of Jeff Vieira (63). They were maintained
in Dulbecco’s modified Eagle’s medium (DMEM) (Cellgro) containing 10%
FBS, 1% P-S, and 0.005 mg/ml of puromycin (for selection). HEK293 cells and
HEK293/TLR3 cells were maintained in DMEM containing 5% FBS and 1% P-S
and in DMEM containing 5% FBS, 1% P-S, and 0.005 mg/ml of Blasticidin
(InvivoGen), respectively. Sf9 cells were maintained in Sf-900 serum-free me-
dium containing amphotericin B (0.25 g/ml) and P-S (0.1%). Sf9 cells were
grown at 30°C under 5% CO2 in a monolayer.
Virus production and purification. A baculovirus vector encoding KSHV
ORF50/Rta was the kind gift of Jeff Vieira (63). Baculovirus ORF50 was am-
plified in Sf9 cells for 72 h, after which time the cell debris was pelleted and the
supernatant stored at 4°C. Vero cells stably expressing KSHV-green fluorescent
protein were then infected with baculovirus ORF50 in DMEM (without phenol
red) containing 2% FBS, 1% P-S, and 17 l of 1 M sodium butyrate to allow
reactivation of the latent KSHV. After 72 h, the supernatant was harvested, cell
debris pelleted, and the supernatant filtered through a sterile 0.45-m filter. In
order to concentrate the virus, 28 ml of supernatant was layered over an 8-ml
cushion of 20% sucrose (optical grade; Sigma), and the virus was pelleted by
ultracentrifugation in an SW28 swinging-bucket rotor for 5 h at 4°C in a Beck-
man ultracentrifuge. The supernatant was decanted, and the virus pellet was
resuspended in sterile phosphate-buffered saline in 1% of the original volume.
The UV inactivation of KSHV was measured by infecting HEK293 cells with
either wild-type (WT) or UV-inactivated recombinant KSHV virus and by de-
termining the green fluorescence for 1 to 5 days postinfection. While the WT
KSHV-infected HEK293 cell line showed infected green cells 24 h postinfection,
the UV-inactivated virus did not show any infected green cells 5 days postinfec-
tion.
THP-1 and primary human monocyte infections. THP-1 cells were infected via
a method called “spinoculation.” A total of 1  106 THP-1 cells were plated in
a six-well dish in supplement-free RPMI 1640 medium. Either 2.5 ml (noncon-
centrated virus) or 100 l (concentrated virus) was added to a total volume of 3
ml/well. Polybrene (4 g/l, 1,000) was added to a final concentration of 1.
The cells were centrifuged in a tabletop centrifuge for 90 min at 2,500 rpm and
30°C. Following centrifugation, the inoculum was removed and replaced with
fresh RPMI 1640 medium (no supplement). The infected cells were incubated
overnight (16 h) at 37°C. This protocol was also followed for HEK293 and
HEK293/TLR3 cell infections with KSHV. In certain instances, virion pellets
were treated with 2 l of RNase A (Sigma) per 100 l of virus or 2 l of buffer
alone for 1 h at 37°C. For experiments with small interfering RNA (siRNA),
THP-1 cells were nucleofected with a plasmid containing an siRNA specific to
TLR3, psiTLR3 (Invivogen), along with a control plasmid containing an siRNA
specific to the luciferase gene, psiLUC (Invivogen). Twenty-four hours later,
these cells were infected with KSHV. This protocol was also used in the analysis
of the THP-1 cell response to poly(I:C) treatment following transfection with
psiTLR3 and psiLUC. Three micrograms of each siRNA plasmid was transfected
into THP-1 cells, followed by treatment with poly(I:C) (75 g/ml) at 48 h
posttransfection. Primary human monocytes were infected in the same manner as
described above except that 1  105 CD14-positive primary human monocytes
(purchased from Lonza, Inc.) were either mock infected or KSHV infected.
Following infection, the cells were maintained in 12% FBS plus 10 ng/ml mono-
nuclear phagocyte colony-stimulating factor for 16 h.
First-strand synthesis and quantitative real-time PCR (qPCR). Following
infection, RNA from THP-1 cells was isolated using Trizol (Invitrogen). RNA
was resuspended in 50 l of RNase-free water and treated with 1 unit of RQ1
DNase (Promega) for 1 h at 37°C. Following DNase treatment, the RNA samples
were phenol-chloroform extracted and precipitated.
RNA was prepared for first-strand synthesis by the resuspension of the RNA
pellet in 17 l of RNase-free water. The first-strand synthesis was carried out
using a first-strand synthesis kit (SuperArray catalogue no. C-01) per the man-
ufacturer’s instructions. The first-strand reaction mixture was increased to a total
volume of 100 l with distilled water. The SuperArray TLR PCR array (APH-
018) was used to analyze the cDNA obtained from infected cells for the activa-
tion of the TLRs or any of the downstream genes in each of the pathways. Each
96-well plate contained 84 genes related to the human TLR pathway. Plates were
prepared according to the manufacturer’s instructions. The plates were run on an
ABI 7000 or ABI 7300 machine, using the following protocol: 95°C for 10 min (1
cycle), 95°C for 15 seconds and 60°C for 1 min (data collection point) (40 cycles),
followed by a dissociation profile and 95°C for 15 seconds, 60°C for 1 min, and
95°C for 15 seconds (1 cycle). All activation increases were normalized to -actin
expression in the samples. The qPCR profiling of the TLR pathway genes after
KSHV infection of THP-1 cells was repeated more than 15 times.
CXCL10 (IP-10) ELISA. An enzyme-linked immunosorbent assay (ELISA)
specific for CXCL10 (human IP-10) (BD) was used to analyze the amount of
protein secreted from KSHV-infected THP-1 cells. Briefly, plates were coated
overnight with capture antibody, washed the following morning, and blocked
with phosphate-buffered saline–Tween. Samples were then added and incubated
for 2 h at room temperature. After 2 h, the plate was washed and an antibody-
enzyme solution was added, per the manufacturer’s instructions, for 1 hour. The
plate was then washed, and substrate solution (ABTS [2,2-azinobis(3-ethyl-
benzthiazolinesulfonic acid)]) (Pierce) was added for 30 min, after which time
the absorbance at 405 nm was determined. The standard (provided by the
manufacturer) was plotted, and the concentration for each sample was deter-
mined based on the standard curve.
siRNA inhibition of TLR3. THP-1 cells were nucleofected (amaxa) with either
3 or 8 g of the psiTLR3 (InvivoGen) or psiLUC (InvivoGen) plasmid. At 48 h
posttransfection, cells were harvested for RNA analysis as described above or for
protein analysis, in which case cells were harvested using radioimmunoprecipi-
tation buffer. Protein was quantified by the Bradford assay (13a), and equal
amounts of protein were loaded onto a 10% sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis gel. Western blotting was performed with an anti-
TLR3 antibody (InvivoGen).
Luciferase assay. Luciferase assays were performed to measure the activation
of NF-B in response to KSHV infection in HEK293 cells stably transfected with
TLR3. The plasmid, pGL3-ELAM-luc, was obtained from Addgene (Addgene
plasmid 13029). A total of 1  105 HEK293 or HEK293/TLR3 cells were
subjected to FuGENE 6 transfection with pELAM NF-B (13). At 24 h post-
transfection, the cells were infected via spinoculation as described above. Sixteen
hours postinfection, the cells were lysed, and the lysates were analyzed as de-
scribed previously (13). This assay was also performed for HEK293 and HEK293/
TLR3 cells following treatment with poly(I:C) at a concentration of 50 g/ml. All
luciferase values were normalized to the protein amount. The same protocol was
used to measure KSHV activation of NF-B in THP-1 cells. Briefly, THP-1 cells
were transfected with the pELAM NF-B plasmid for 48 h, at which time the
cells were infected with KSHV for 24 h. The total protein was isolated from the
cells at 24 h postinfection and subjected to a luciferase assay.
Cytokine array analysis. A human cytokine antibody array (RayBiotech) was
used to quantify the overall activation pattern following KSHV infection of
monocytes. The protocol was performed as described by the manufacturer.
Briefly, each array membrane was blocked and then incubated for 2 h at room
temperature with undiluted supernatant collected from either KSHV-infected
THP-1 cells or mock-infected THP-1 cells. The arrays were then washed and
incubated with biotin-conjugated antibody solution, specific to each array, for
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2 h. The membranes were washed again and then incubated with a horseradish
peroxidase-conjugated streptavidin solution for 2 h, followed by a wash step.
Arrays were exposed to detection buffer and then exposed to X-ray film. Quan-
titation of the individual dots was done using the ImageJ program.
RESULTS
Activation of the TLR3 pathway upon KSHV infection of
THP-1 monocytes. To determine the effect of KSHV infection
on the TLR pathway in monocytes, we first analyzed the mRNA
expression levels of all 10 TLRs in THP-1 cells in response to
KSHV infection. A total of 1  106 THP-1 monocytes were
infected with WT recombinant KSHV virus (rKSHV.219) (63).
Infections were carried out via spinoculation, and the RNA was
isolated at 16 h postinfection. RNA was reverse-transcribed to
cDNA. Subsequent to first-strand synthesis, qPCR was per-
formed using an array containing all 10 human TLRs and 74
additional genes involved in the different TLR signaling pathways.
All data were normalized to those for -actin, used as a control.
To ensure that the THP-1 cells were infected with KSHV, qPCR
for the latency-associated nuclear antigen (LANA) was per-
formed, and LANA mRNA expression was detected 16 h postin-
fection only in the KSHV-infected THP-1 cells at a sixfold higher
level than that of mock-infected cells (data not shown). LANA
mRNA has previously been shown to be expressed very early after
primary infection in other cell types (35). Analysis of the TLR
qPCR array suggested that TLR3 expression was specifically up-
regulated in response to KSHV infection of monocytes (Table 1).
The upregulation of TLR3 was consistently between 8- and 15-
fold greater than that of mock-infected cells. To confirm that our
activation of TLR3 was specific to the infectious virus, we UV
inactivated KSHV prior to the infection of THP-1 cells and per-
formed the same infection followed by qPCR evaluation. THP-1
cells infected with UV-inactivated KSHV showed no significant
upregulation of TLR3 (or any other TLRs), indicating that the
activation observed in our experiments is due primarily to infec-
tious virus (Table 1).
In order to confirm the upregulation of TLR3 by KSHV, we
also performed conventional reverse transcriptase PCR (RT-
PCR) with RNA from WT and UV-inactivated, KSHV-infected
THP-1 cells with a different set of TLR3-specific primers. Using
this independent assay, we again found that KSHV infection
specifically upregulated the expression of TLR3 (Fig. 1A).
Since TLR3 can be activated by RNA molecules, we wanted
to test the possibility that our virion preparation and purifica-
tion procedures were contaminated with free RNAs. We rea-
soned that viral RNAs that were present inside the infectious
virion (9, 14) would be protected from RNase treatment but
that any contaminating, superfluous RNAs that had copurified
with our infectious virions would not be protected from RNase
treatment. We pelleted KSHV virions through a sucrose cush-
ion and then split the pellet in half. One fraction was treated
with RNase and incubated at 37°C for 1 hour while the other
fraction was incubated with buffer without RNase. We next
infected THP-1 cells with the RNase-treated and untreated
virion samples. Cells were harvested at 16 h postinfection, and
RNA was isolated and subjected to real-time PCR as described
above. Figure 1B shows the relative mRNA expression level of
TLR pathway genes in cells infected with RNase-treated virus
or untreated virus. As shown in Fig. 1B, the expression levels of
all TLR pathway genes, including TLR3, were very similar, and
RNase treatment of the virus did not reduce TLR3 or CXCL10
mRNA levels. This suggests that KSHV is truly activating
TLR3 expression and that TLR3 upregulation is not due to
contaminating RNAs present in the viral preparation. We also
detected a very modest (less-than-threefold) upregulation of
mRNAs of other endosomal TLRs, including TLR7, TLR8,
and TLR9 (data not shown), but the upregulation was insig-
nificant compared to TLR3 induction levels.
KSHV activates TLR3-responsive CXCL10, IFN-1, CCL2
(MCP-1), and IRF-1 genes. Although increased TLR3 gene
expression is not a requirement for TLR3 activation, it appears
that KSHV specifically upregulates TLR3 at the transcrip-
tional level, leading to the activation of downstream targets of
TLR3, such as CXCL10, IFN-1, CCL2 (monocyte chemoat-
tractant protein 1 [MCP-1]), and IRF-1.
CXCL10 (or IP-10) is a member of the CXC family of
chemokines and is a strong attractant of Th1 lymphocytes and
monocytes (57, 58). CXCL10 induction upon the treatment of
cells with the dsRNA homolog poly(I:C) is characteristic of
TLR3 activation (25, 45, 48). CXCL10 has also been shown to
be induced in astrocytes upon treatment with poly(I:C), and
CXCL10 secretion upon respiratory syncytial virus infection of
MRC-5 cells has been shown to be dependent on TLR3 stim-
ulation (45). Interestingly, Teruya-Feldstein et al. have also
found that CXCL10 was associated with Epstein-Barr virus
lymphoproliferative diseases, such as lymphomatoid granulo-
matosis, nasal T-cell or natural killer (NK)-cell lymphomas,
and Hodgkin’s lymphoma (59, 60).
In this study, we show that CXCL10 is dramatically upregu-
lated in response to KSHV infection of monocytes (Table 1).
qPCR analysis showed that the mRNA level of CXCL10 was
increased 700-fold more than that of mock-infected THP-1
cells. Furthermore, in cells infected with UV-inactivated
KSHV, there was no induction of CXCL10, similar to the
outcome for mock-infected cells. To confirm our results, we
performed conventional RT-PCR with a different set of
CXCL10 primers with RNA isolated from WT and UV-in-
fected THP-1 cells and found that the mRNA levels of
CXCL10 were vastly increased in WT KSHV-infected THP-1
cells (Fig. 1A).
To confirm this observation at the protein level, we performed
a sandwich ELISA assay for CXCL10. The plates were coated
overnight, blocked the following day, and then incubated with
supernatant collected from KSHV-infected THP-1 cells. As
TABLE 1. TLR pathway genes activated upon KSHV infection
of monocytes
Gene product Function Increase (fold) inmRNA levela




IRF1 Interferon regulatory factor 12.81
IL-6 Cytokine 6.73
EIF2AK2/PKR RNA-activated kinase 11.26
MyD88 TLR adaptor molecule 5.92
CD80 B-lymphocyte activation antigen 11.36
a Over that in mock-infected cells.
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FIG. 1. KSHV activates the gene expression of the TLR3 pathway. (A) Conventional RT-PCR of TLR3 and CXCL10 from mock-infected,
KSHV-infected, or UV-irradiated and KSHV-infected THP-1 cells. Lanes: 1, 1-kb ladder; 2, TLR3, mock infected; 3, TLR3, KSHV infected; 4,
TLR3, UV irradiated and KSHV infected; 5, 1-kb ladder; 6, CXCL10, mock infected; 7, CXCL10, KSHV infected; 8, CXCL10, UV irradiated and
KSHV infected. (B) RNase treatment of KSHV virions does not alter the TLR3 activation profile. Shown are the mRNA increases after the
infection of THP-1 cells with WT KSHV and RNase-treated KSHV. There was no significant difference between the mRNA levels of the activated
genes in the KSHV-infected cells and those of cells infected with RNase-treated KSHV virus. (C) Comparison of CXCL10 protein secretion levels
from mock-infected, KSHV-infected, and UV-irradiated KSHV-infected cells. KSHV-infected cells consistently produced an average of 15 to 20
ng/ml of CXCL10. The mock-infected and the UV-irradiated and KSHV-infected cells did not secrete any CXCL10 protein. (D) IFN-1 secretion
from mock-infected and KSHV-infected cells. KSHV-infected THP-1 cells produced approximately 65 pg/ml of IFN-1. The mock-infected and
the UV-irradiated KSHV-infected cells did not secrete IFN-1. (E) RT-PCR of TLR3 and CXCL10 from mock- and KSHV-infected CD14-
positive primary human monocytes.
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shown in Fig. 1C, WT KSHV infection induced very high levels of
CXCL10 in monocytes, in the range of 10 to 20 ng/ml.
In addition to CXCL10, we found that IFN-1, CCL2 (MCP-
1), and IRF-1 mRNAs were all upregulated by KSHV infection of
THP-1 cells compared to the levels in mock-infected cells (Table
1). IFN-1 is a member of the IFN family of proteins and is
involved in the innate immune response; specifically, activation of
IFN-1 is induced upon activation of TLRs. Multiple studies have
determined that IFN-1 is upregulated in response to TLR3
activation (36, 42, 51, 62). Poly(I:C), a homolog of dsRNA which
is known to stimulate TLR3, has been shown to induce IFN-1 in
multiple cell lines. Astrocytes, human corneal epithelial cells, and
human primary uterine epithelial cells all produce elevated levels
of IFN-1 in response to the TLR3 ligand poly(I:C) (36, 42, 51,
62). We consistently observed an 35-fold increase in the mRNA
expression of IFN-1 (Table 1) upon infection of THP-1 cells
with KSHV. We confirmed this increase of IFN-1 mRNA levels
in monocytes by performing an IFN-1 ELISA (Fig. 1D). In
KSHV-infected cells, approximately 70 pg/ml of IFN-1 was be-
ing secreted into the surrounding media at 16 h postinfection
compared to no secretion of IFN-1 from mock-infected cells.
CCL2 (MCP-1) is a chemokine that has been implicated in the
recruitment of a variety of immunoresponsive cells, including
monocytes, T lymphocytes, and NK cells. There are also multiple
examples of CCL2 activation in response to the TLR3 ligand
poly(I:C) (25, 51). Thus, TLR3 agonists lead to the upregulation
of the chemokine CCL2. We consistently observed a 25- to 30-
fold induction in the expression level of CCL2 in response to
KSHV infection in THP-1 monocytes (Table 1).
IRF-1 is an interferon regulatory factor that has been shown
to control the transcription of CXCL10 through binding to an
IFN-stimulated response element (ISRE) on the promoter of
CXCL10. IRF-1 has previously been shown to respond to
TLR3 stimulation via poly(I:C) treatment in HT29 human
intestinal epithelial cells (52). Furthermore, IRF-1 is essential
for IFN-1 and CXCL10 expression after reovirus infection in
human lung fibroblasts (28). This evidence points to a pivotal
role for IRF-1 in TLR3 signaling, directly contributing to the
upregulation of CXCL10. We consistently detected an 12-
fold increase in IRF-1 transcription upon the infection of
THP-1 monocytes with KSHV (Table 1).
We have also examined the upregulation of TLR3 and
CXCL10 upon KSHV infection of CD14-positive primary hu-
man monocytes (Fig. 1E) and found that there was a 15- and
1,200-fold upregulation in the levels of TLR3 and CXCL10,
respectively, upon KSHV infection. Altogether, our RNA pro-
filing and protein analyses are consistent with TLR3 upregu-
lation upon KSHV infection of monocytes.
Specificity of TLR3 activation by KSHV. We performed
Western blotting for TLR3 expression on KSHV-infected
FIG. 2. siRNA against TLR3 diminishes the induction of CXCL10, IFN-1, and IRF-1 gene expression from KSHV-infected THP-1 cells.
(A) Western blot of TLR3 protein levels in KSHV-infected or mock-infected THP-1 cells. (B) THP-1 cells were nucleofected with a control
luciferase siRNA plasmid, psiLUC (lane 1), or a TLR3-specific siRNA plasmid, psiTLR3 (lanes 2 [3 g psiTLR3] and 3 [8 g psiTLR3]), followed
by KSHV infection and Western blotting for TLR3. (C) THP-1 cells were nucleofected with 3 g control siRNA or a TLR3-specific siRNA
plasmid, psiTLR3. Real-time PCR profiling of TLR pathway genes indicated a significant reduction in the increase of mRNA upon pretreatment
of THP-1 cells with the siRNA specific to TLR3, indicating that these downstream genes are specifically activated through TLR3 in response to
KSHV infection. (D) THP-1 cells were nucleofected with 3 g control siRNA (siLUC) or TLR3-specific siRNA (psiTLR3). Cells were infected
with KSHV, and CXCL10 was measured 16 h postinfection. The CXCL10 ELISA shows a 70% decrease in CXCL10 secretion from KSHV-
infected THP-1 cells transfected with psiTLR3 compared to cells transfected with psiLUC. (E) THP-1 cells were transfected with 3 g of psiTLR3
or psiLUC. At 48 h posttransfection, cells were treated with poly(I:C) for 24 h. RNA was harvested and subjected to RT-PCR using TLR3 and
CXCLIO primers.
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THP-1 cells. We found that TLR3 protein levels were also
increased in KSHV-infected THP-1 cells 16 hours postinfec-
tion compared to those in mock-infected cells (Fig. 2A).
We next confirmed that we could suppress the expression of
the TLR3 protein via the expression of an siRNA plasmid
specific to TLR3. THP-1 cells were nucleofected with different
amounts of the TLR3-specific siRNA plasmid, psiTLR3, or a
control luciferase-specific siRNA plasmid, psiLUC (Invivo-
gen), prior to KSHV infection. After KSHV infection, cells
were harvested and the cell lysates were analyzed by immuno-
blotting with a TLR3-specific antibody. As shown in Fig. 2B,
the psiTLR3 plasmid (Fig. 2B, lanes 2 and 3) efficiently re-
duced the amount of TLR3 protein compared to that in the
cells transfected with psiLUC (Fig. 2B, lane 1).
We next tested the specificity of TLR3 activation upon
KSHV infection by knocking down the expression of TLR3
with siRNA against TLR3 in THP-1 monocytes prior to KSHV
infection. THP-1 cells were nucleofected with 3 g of a TLR-
specific siRNA plasmid, psiTLR3 (Invivogen), or psiLUC.
Forty-eight hours posttransfection, THP-1 cells were infected
with KSHV as described above. At 16 hours postinfection, the
RNA was isolated and analyzed by both qPCR and conven-
tional RT-PCR. Analysis by both methods (qPCR and conven-
tional PCR) showed that in cells transfected with psiTLR3, the
level of genes in the TLR3 pathway was significantly reduced
compared to that of the cells transfected with psiLUC after
KSHV infection. This included TLR3 itself and its downstream
targets CXCL10, IFN-1, CCL2, and IRF-1 (Fig. 2C). Consis-
tently, the cells transfected with psiTLR3 showed a significant
reduction in mRNA expression levels. TLR3 mRNA expres-
sion was reduced 3-fold, CXCL10 mRNA expression was
reduced 70-fold, IFN-1 mRNA expression was reduced
2.5-fold, CCL2 mRNA expression was reduced 3-fold, and
IRF-1 mRNA expression was reduced 4-fold (Fig. 2C). Inter-
estingly, we did not find that IL-6 mRNA levels were affected
by TLR3-specific siRNA, suggesting that it is not upregulated
as a consequence of TLR3 activity.
We also measured CXCL10 in cells that had been trans-
fected with psiTLR3 or the control psiLUC by ELISA. We
found that siRNA against TLR3 reduced the amount of
CXCL10 protein production by 70% (Fig. 2D). Thus, KSHV
specifically upregulates the TLR3 pathway in infected mono-
cytes, and this activation can be inhibited by TLR3-specific
siRNA treatment.
For a control, we performed the same analysis using the
TLR3 agonist poly(I:C) instead of KSHV infection. THP-1
cells were transfected with 3 g of psiTLR3 or psiLUC. Forty-
eight hours postinfection, cells were treated with 75 g/ml
poly(I:C) for 24 h. RNA was harvested and subjected to qPCR
using TLR3- and CXCL10-specific primers. We found that the
psiLUC-transfected THP-1 cells showed approximately a 2.5-
fold increase in CXCL10 and a 2-fold increase in TLR3 mRNA
levels after poly(I:C) stimulation (Fig. 2E). This level of acti-
vation of TLR3-responsive genes upon poly(I:C) treatment of
THP-1 cells corresponds well with what has previously been
shown for the poly(I:C) stimulation of THP-1 cells (56). For
example, Saitoh et al. have previously shown that the poly(I:C)
stimulation of THP-1 cells induces only a twofold activation of
an ISRE reporter construct through TLR3 signaling (46). This
is in contrast to the poly(I:C) stimulation of HEK293/
TLR3cells, which induces a 10-fold induction of the same
ISRE reporter construct through poly(I:C)-mediated TLR3
signaling (46). Furthermore, the poly(I:C)-stimulated increase
of TLR3 and CXCL10 was ablated in THP-1 cells treated with
psiTLR3 (Fig. 2E), and the psiTLR3-transfected THP-1 cells
were unable to respond to poly(I:C) stimulation.
KSHV infection induces NF-B activation in HEK293 cells
expressing TLR3. One endpoint of TLR signaling is the acti-
vation of NF-B (3, 4). To determine whether KSHV infection
of HEK293 cells would induce NF-B via the TLR3 signaling
pathway, we used HEK293 cells stably transfected with TLR3.
Equal amounts of both native HEK293 cells and TLR3-ex-
pressing HEK293 cells (HEK293/TLR3) were transfected with
an NF-B luciferase reporter plasmid. At 24 h posttransfec-
tion, both cell lines were infected with KSHV. Cells were
harvested at 16 h posttransfection, and luciferase assays were
performed. On average, the KSHV-infected HEK293/TLR3
cells showed an approximately fivefold increase in luciferase
activity compared to that in mock-infected HEK293/TLR3
cells (Fig. 3A). Additionally, KSHV-infected HEK293/TLR3
cells showed an approximately fivefold increase in NF-B com-
pared to that in mock-treated HEK293 cells (Fig. 3B). As a
control, we also treated HEK293 and HEK293/TLR3 cells with
the TLR3 agonist poly(I:C). The poly(I:C)-treated HEK293/
TLR3 cells showed an approximately eightfold increase in lu-
ciferase activity compared to that in mock-treated HEK293/
TLR3 cells (Fig. 3A), and the same trend occurred in the
poly(I:C)-treated HEK293/TLR3 cells compared to the HEK293
cells (Fig. 3B). These data demonstrate that KSHV triggers the
TLR3 signaling pathway, leading to the upregulation of the
transcription factor NF-B. We also infected THP-1 cells
transfected with the NF-B reporter plasmid as described
above. Briefly, THP-1 cells were transfected with 1 g of the
pELAM–NF-B reporter plasmid and incubated for 48 h. The
transfected cells were subsequently infected with KSHV and
incubated for another 24 h. At 24 h postinfection, the total
protein was harvested and subjected to a luciferase assay. We
found that KSHV infection induced a 2.5-fold increase in
NF-B activity in infected THP-1 cells compared to that in
mock-infected cells (Fig. 3C).
KSHV infection of THP-1 monocytes upregulates the pro-
duction of a multitude of cytokines, chemokines, and growth
factors. From our TLR profiling, we found that KSHV upregu-
lates the expression of TLR-responsive cytokines/chemokines,
and we next queried whether the virus was activating a wider
range of cytokines. In order to do this, we analyzed the super-
natants of KSHV-infected THP-1 cells for the upregulation of
a large number of secreted cytokines, chemokines, and growth
factors by using antibody arrays. Infections were carried out as
described above, and the supernatants from the KSHV-in-
fected cells were analyzed by a cytokine antibody array. Anti-
body arrays spotted with 120 cytokine antibodies were blocked,
washed, and incubated with the supernatants from the virus-
infected THP-1 cells. Following incubation with the superna-
tants, the blots were washed again and probed with primary
antibody, followed by probing with secondary antibody. As
shown in Table 2, approximately 12 cytokines, chemokines,
and growth factors were upregulated in response to KSHV
infection of monocytes. Included among those were CCL2
(MCP-1) and IL-6, both of which were also increased at the
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FIG. 3. KSHV infection of HEK293/TLR3 (293-TLR3) cells leads to NF-B activation. (A) Activation of an NF-B-driven luciferase construct
in response to KSHV infection of HEK293/TLR3 stable cells. HEK293/TLR3 stable cells were transfected with an NF-B–luciferase reporter
plasmid, followed by mock infection or infection with KSHV. KSHV-infected cells showed a fivefold increase in luciferase activity compared to
that in the mock-infected cells, indicating the activation of NF-B in HEK293/TLR3 cells upon infection with KSHV. Cells treated with the TLR3
agonist poly(I:C) showed an 8.5-fold increase in luciferase activity compared to that in the mock-infected cells, confirming that TLR3 stimulation
in HEK293/TLR3 cells leads to NF-B activation. (B) Activation of an NF-B-driven luciferase construct in response to KSHV infection of
HEK293 versus HEK293/TLR3 cells. HEK293 and HEK293-TLR3 cells were transfected with an NF-B–luciferase reporter plasmid and infected
with KSHV 24 h posttransfection. Cells stably expressing TLR3 showed a fivefold increase in luciferase activity compared to the activity in HEK293
cells after infection with KSHV, indicating a specific role for TLR3 induction of NF-B. Similarly, poly(I:C)-treated HEK293/TLR3 cells showed
an 8.5-fold increase in NF-B activity compared to that in poly(I:C)-treated HEK293 cells. (C) Activation of an NF-B-driven luciferase construct
in response to KSHV infection of THP-1 cells. KSHV-infected THP-1 cells were transfected with the NF-B reporter plasmid for 48 h. The cells
were then infected with KSHV for 24 h. Twenty-four hours postinfection, the total protein was harvested and the NF-B luciferase activity was
measured. The KSHV-infected THP-1 cells showed a 2.5-fold increase in NF-B activity compared to that in mock-infected THP-1 cells transfected
with the same NF-B reporter plasmid.
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mRNA level in response to KSHV infection of THP-1 mono-
cytes. In addition to CCL2 and IL-6, we found eight other
cytokines and growth factors whose expression levels were
increased upon KSHV infection. These include platelet-de-
rived growth factor BB, placental growth factor, vascular en-
dothelial growth factor, vascular endothelial growth factor D,
and the cytokines/chemokines GRO-	,,
, GRO-	, HCC-4,
and oncostatin M. Additionally, the neuropeptide agouti-re-
lated protein and the adipokine leptin were also activated upon
KSHV infection of monocytes.
DISCUSSION
Here we report the first evidence of a role for TLRs in the
host response to infection by KSHV. The data presented above
demonstrate that KSHV stimulates TLR3 gene expression
upon infection of THP-1 and CD14-positive primary human
monocytes. This is also the first evidence of a human DNA
tumor virus activating the expression of TLR3, a TLR that
hitherto has been implicated only as a sensor of RNA viruses.
There are several possible explanations for how KSHV is ac-
tivating TLR3. Most likely is the possibility that a viral gene
product may directly activate TLR3 transcription, since the
UV inactivation of KSHV did not result in TLR3 upregulation.
This is consistent with the need for infectious virus to upregu-
late TLR3 activation, as has been previously shown for influ-
enza A virus infection of lung epithelial cells. Only viable
influenza A virus, not UV-inactivated influenza A virus, could
activate TLR3 signaling (27). Another possibility is that since
TLR3 resides in the endosomal membrane and the endoplas-
mic reticulum and since KSHV has previously been shown to
enter cells through endocytosis (6), the virus may encounter
TLR3 in the endosome. Human cytomegalovirus contains
RNAs in the virion (14), and recently, Bechtel et al. have
shown that KSHV encapsidates 11 specific viral transcripts in
its virion (9). These viral RNAs could activate TLR3 upon viral
entry and uncoating in the endosome. It is even plausible that
the newly discovered KSHV microRNAs (17, 47) are con-
tained in the KSHV virion and that they activate TLR3. Re-
gardless of the mechanism, recent clinical data prove that
TLR3 can control herpesvirus infection, since children with a
TLR3 deficiency were very susceptible to HSV-1-induced en-
cephalitis (68). Hence, the fact that our data demonstrate that
KSHV activates the TLR3 pathway may be very relevant with
respect to KSHV infection and herpesviral infection in general.
We found that TLR3 upregulation by KSHV in monocytes
induces a number of cytokines and chemokines, including IFN-
1, CCL2, and CXCL10. Previous work has shown that
CXCL10 is specifically upregulated through the activation of
TLR3 (36, 41, 42, 45). CXCL10 mRNA upregulation was the
most significant, with up to a 743-fold increase over that of
mock-infected cells. This was much higher than the upregula-
tion of poly(I:C)-treated THP-1 cells. We also observed a con-
comitant increase in CXCL10 protein levels upon KSHV in-
fection compared to those of mock-infected monocytes. We
surmise that CXCL10 may play a role in the recruitment of
inflammatory cells to the site of KSHV infection in vivo, since
CXCL10 is a chemoattractant for monocytes (36, 41, 42, 45). A
previous study has established some precedence for a role for
CXCL10 in aiding the maintenance of viral latency. Theil et al.
showed that CXCL10 (IP-10) mRNA expression levels are
strongly induced in HSV-1-infected trigeminal ganglia and that
this chronic immune response seems to aid the maintenance of
viral latency (61). It is possible that CXCL10 plays a similar
role in KSHV infection.
The upregulation of IFN-1, a potent inducer of the antivi-
ral response, is a direct result of the activation of the TLR3
pathway by KSHV, as evidenced by the inhibition of IFN-1
when cells were transfected with TLR3-specific siRNA prior to
KSHV infection. Upregulation of IFN-1 can also be directly
linked to TLR3 activation (36, 42, 51, 62). CCL2, for which we
also observed a strong induction of mRNA levels, is a potent
attractor of NK cells and T lymphocytes (19, 26, 37). In the
context of KSHV infection, CCL2 (MCP-1) has been shown to
play a significant role. Acute KSHV infection of endothelial
cells promotes a strong CCL2 induction, leading to increased
inflammation and the promotion of angiogenesis (20). All of
this evidence taken together suggests that the activation of
CCL2 (MCP-1) upon KSHV infection is advantageous to
KSHV and may promote angiogenesis and the spread of the
virus.
IRF-1 is known to exert transcriptional control over
CXCL10, TLR3, and IFN-1 (16, 28), all of which were ob-
served to be upregulated in KSHV-infected monocytes. It is
possible that TLR3 activation stimulates IRF-1, which in turn
activates both CXCL10 and IFN-1, leading to the promotion
of the inflammatory response and a positive feedback loop.
Why does KSHV induce the TLR3 pathway? One strategy
for viruses to establish latency is to stimulate an immune re-
sponse, which can lead to cytokine release and NF-B activa-
tion. Indeed, NF-B, a downstream target of TLR3 activation,
is critical for the establishment of KSHV latency (15). The goal
of KSHV is to establish a latent infection that will persist
within the host and last for the lifetime of the host. It is also
possible that KSHV, via the activation of TLRs and specifically
TLR3 in monocytes, initiates the inflammatory response to
recruit cells to the site of infection, where it can spread and
establish latency. Such a scenario has been reported for West
Nile virus (WNV), in which TLR3 appears to enhance the
ability of WNV to replicate and spread in the brain (64). Wang
et al. suggested that TLR3 mediates an innate immune re-
TABLE 2. Increase in protein levels after KSHV infection
of monocytes
Proteina Function Increase (fold) inprotein level






Oncostatin M Cytokine 6.00
PIGF Growth factor 5.50
VEGF Growth factor 3.00




a PDGF-BB, platelet-derived growth factor BB; AgRP, agouti-related protein;
PIGF, placental growth factor; VEGF, vascular endothelial growth factor;
VEGF-D, vascular endothelial growth factor D.
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sponse, which is used by WNV to gain entry into the central
nervous system and induce encephalitis (64). We propose that
KSHV capitalizes on TLR3’s activation of CXCL10 and CCL2
to spread to other cells through CXCL10-induced chemotaxis
of immune cells to the site of infection and through CCL2-
mediated angiogenesis and vascularization. We find that four
downstream TLR3 effectors (CXCL10, IRF-1, CCL2, and
IFN-1) are specifically upregulated by KSHV infection.
These effectors are known to be involved in the initiation or
progression of the inflammatory response.
It is important to note that this induction is seen upon
primary infection of monocytes. At later times, it is likely that
these proinflammatory genes are downregulated, since KSHV
encodes a number of viral genes that aid in the suppression of
the antiviral response (23, 40, 44). We speculate that activation
of an innate immune response by KSHV might actually aid the
virus in the establishment of latency. If there were no innate
immune response to KSHV infection, the virus would replicate
and likely prove fatal for the host, as has been suggested for the
infection of human cells by the simian herpes B virus (24, 65).
Thus, the activation of the host innate immune response
against KSHV not only helps to curb viral replication and viral
spread but also induces a selective pressure on the virus to
establish a latent state. This allows the virus to evade the
subsequent wave of adaptive immune host responses that nor-
mally follows an effective innate immune response. Thus, in
summary, KSHV can capitalize on the host innate immune
response, which is used to the advantage of the virus.
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